Jun 30, 2026 08:02AM
Jun 30, 2026 08:00AM
May 11, 2026 04:23PM
Mar 31, 2026 07:06AM
Mar 31, 2026 06:40AM
Mar 31, 2026 06:40AM
Mar 4, 2026 04:20PM SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Feb 26, 2026 08:23AM
Feb 26, 2026 08:23AM
Jan 28, 2026 08:00AM
Jan 21, 2026 08:01AM
Jan 21, 2026 08:00AM
Dec 22, 2025 08:02AM
Dec 22, 2025 08:00AM SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Nov 19, 2025 07:00AM
Nov 17, 2025 10:16AM
Nov 17, 2025 10:15AM
Nov 5, 2025 04:20PM
Oct 28, 2025 07:14AM
Oct 15, 2025 08:01AM
Oct 15, 2025 08:00AM SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
Sep 30, 2025 08:00AM
Sep 30, 2025 08:00AM
Sep 4, 2025 08:30AM
Aug 25, 2025 08:00AM
Aug 13, 2025 04:30PM
May 28, 2025 08:31AM
May 28, 2025 08:30AM SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
May 15, 2025 04:20PM
Apr 8, 2025 08:05AM
Apr 8, 2025 08:00AM
Mar 12, 2025 05:08PM
Dec 18, 2024 08:00AM
Nov 6, 2024 04:30PM
Oct 10, 2024 08:00AM SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
Oct 3, 2024 08:00AM
Aug 27, 2024 08:00AM
Aug 8, 2024 04:30PM
Jul 23, 2024 07:02AM
Jul 23, 2024 07:00AM
May 8, 2024 04:30PM
Apr 30, 2024 04:05PM SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
Apr 9, 2024 04:05PM
Mar 28, 2024 04:01PM
Jan 30, 2024 04:05PM
Jan 29, 2024 05:15PM
Jan 29, 2024 05:15PM
Jan 5, 2024 09:00PM
Jan 5, 2024 09:45AM SCYNEXIS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly T
Jan 5, 2024 08:30AM

325,726 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All